Replay available

BioCardia, Inc. (BCDA) Q3 2025 Earnings Call

BioCardia, Inc. (NASDAQ: BCDA) Q3 2025 earnings conference call, held 2025-11-12. Replay captured from the company's public earnings webcast.

Wed, November 12, 2025 at 4:30 PMendedReplay
BioCardia, Inc. (BCDA) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

David McClung

Chief Financial Officer

Raja Kumara Guru

Analyst, Brookline Capital Markets

Miranda Pato

Investor Relations

James Malloy

Analyst, Alliance Global Partners

Peter Altman

President and Chief Executive Officer

Replay transcript excerpt

Good afternoon and welcome to the BioCardia third quarter financial results and business update conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touch screen or keypad. To withdraw your question, please press star, then two. Participants of this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately one hour after the end of the call. I would now like to turn the call over to Miranda Pato of BioCardia Investor Relations. Please go ahead, Miranda. Thank you. Good afternoon, and thank you for participating in today's conference call. Joining me from BioCardia's leadership team are Peter Altman, President and Chief Executive Officer, and David McClung, the company's Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address BioCardia's expectations for future performance and operational results, references to management's intentions, beliefs, projections, outlook, analyses, and current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products, technologies, and obtaining regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors and cautionary statements described in Biocardia...

More from Biocardia, Inc.